Human cardiovascular progenitor cells
AssigneeIcahn School of Medicine at Mount Sinai
InventorsGordon M. Keller, Lei Yang, Steven Kattman
Life of this patent
Estimating the term…
Abstract
The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.
Claims3
A method of generating a population of human cardiomyocytes comprising culturing a population of human cardiovascular progenitor cells that express the tyrosine kinase receptor KDR and do not express the tyrosine kinase receptor C-KIT and VE-CADHERIN in the presence of Dickkopf-1 (DKK1) at a concentration of from about 100 ng/ml to about 200 ng/ml and vascular endothelial growth factor (VEGF) at a concentration of from about 1.0 ng/ml to about 50.0 ng/ml for about seven to about ten days, and harvesting a population of human cardiomyocytes.
A method of generating cardiovascular colonies containing cardiomyocytes, endothelial cells, and vascular smooth muscle cells comprising culturing human cardiovascular progenitor cells that express the tyrosine kinase receptor KDR and do not express the tyrosine kinase receptor C-KIT and VE-CADHERIN in the presence of vascular endothelial growth factor (VEGF) at a concentration of from about 1.0 ng/ml to about 50.0 ng/ml, basic fibroblast growth factor (bFGF) at a concentration of from about 1.0 ng/ml to about 10.0 ng/ml, and Dickkopf-1 (DKK1) at a concentration of from about 100 ng/ml to about 200 ng/ml for about three to about seven days, thereby generating human cardiovascular colonies.
Dependencies are inferred from the claim text.